Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPension (IS)Profit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Harvard Bioscience (HBIO) Other Non Operating Income (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Other Non Operating Income for 16 consecutive years, with -$1.3 million as the latest value for Q4 2025.

  • Quarterly Other Non Operating Income fell 356.4% to -$1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.7 million through Dec 2025, down 717.23% year-over-year, with the annual reading at -$2.7 million for FY2025, 717.23% down from the prior year.
  • Other Non Operating Income for Q4 2025 was -$1.3 million at Harvard Bioscience, down from -$365000.0 in the prior quarter.
  • The five-year high for Other Non Operating Income was $516000.0 in Q4 2024, with the low at -$1.3 million in Q4 2025.
  • Average Other Non Operating Income over 5 years is -$178600.0, with a median of -$180000.0 recorded in 2022.
  • The sharpest move saw Other Non Operating Income soared 453.85% in 2023, then plummeted 1251.11% in 2024.
  • Over 5 years, Other Non Operating Income stood at -$189000.0 in 2021, then surged by 346.03% to $465000.0 in 2022, then crashed by 171.4% to -$332000.0 in 2023, then soared by 255.42% to $516000.0 in 2024, then tumbled by 356.4% to -$1.3 million in 2025.
  • According to Business Quant data, Other Non Operating Income over the past three periods came in at -$1.3 million, -$365000.0, and -$644000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.